Metropolis Healthcare’s Board of Directors has approved an interim dividend of ₹4 per equity share, with a face value of ₹2 each, for the financial year 2025-26. The record date for determining shareholders eligible for the dividend is November 11, 2025. The dividend will be dispatched or credited within 30 days of its declaration. The board also approved the unaudited financial results for Q2 2025.
Interim Dividend Declared
The Board of Directors has declared an interim dividend of ₹4 per equity share (face value of ₹2 each) for the financial year 2025-26. This decision was made during a board meeting on November 4, 2025.
Key Dates
The record date for the interim dividend is November 11, 2025. Payments will be dispatched or credited within 30 days of the declaration date.
Q2 2025 Financial Performance
The Board approved the unaudited standalone and consolidated financial results for the second quarter (Q2 – July-September) of the financial year 2025. Key figures from the standalone results include:
- Revenue from operations: ₹355.71 million
- Total Income: ₹358.23 million
- Profit before tax: ₹621.18 million
- Profit for the period: ₹466.32 million
Subsidiary Acquisitions
During the period, Metropolis Healthcare completed several acquisitions, including:
- Dapic Metropolis Healthcare Private Limited
- Dr. RS Patil’s Ambika Pathology Laboratory
Income Tax Matters
The company is actively addressing income tax assessment orders, having received favorable appellate orders reducing the original demand. These matters are under process.
Source: BSE
